Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2025 10:32 ET | Source: ImCheck Therapeutics SAS

ImCheck Announces Oral Presentation of Updated ICT01 Efficacy Data in First-line AML at the ASCO Annual Meeting 2025

ImCheck Announces Oral Presentation of Updated ICT01 Efficacy Data in First-line AML at the ASCO Annual Meeting 2025 Marseille, France, April 23, 2025 10:00 a.m. ET / 4:00 p.m. CET– ImCheck...
March 28, 2024 08:05 ET | Source: Tevogen Bio Inc

Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price

The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4.
November 03, 2023 14:00 ET | Source: ImCheck Therapeutics SAS

ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023

ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023 Interim data from EVICTION-2 study confirms safety and tolerability...
August 05, 2022 08:00 ET | Source: Hyris

Hyris' New T-Cell Test is Finally Available to EU Countries to Easily Map Patients' Cellular Immunity to SARS-CoV-2

LONDON, Aug. 05, 2022 (GLOBE NEWSWIRE) -- As the pandemic crisis has entered a new phase, it is a common belief among the scientific community that COVID-19 is here to stay, maybe for a long time....
November 09, 2020 09:23 ET | Source: DelveInsight Business Research LLP

T-Cell Surface Glycoprotein CD4 Clinical Trial Analysis by DelveInsight

Los Angeles, USA, Nov. 09, 2020 (GLOBE NEWSWIRE) -- T-Cell Surface Glycoprotein CD4 Clinical Trial Analysis by DelveInsight DelveInsight has recently added “T-cell Surface Glycoprotein CD4 –...